CAR-T cell immunotherapy
Phase 1Cell therapy
CAR-T cell immunotherapy is one of 80 biologic programs targeting Prostate Cancer. It is currently in Phase 1.
2
Indications
8
Total Trials
2
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Paraplatin
AAvyxa
Phase 3
Tecentriq
RochePhase 3
Alinamin
RochePhase 3
Verzenio
Eli LillyPhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Ritalin
NovartisPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunotherapy2 trials
Renal Cell Carcinoma1 trial
T Cells1 trial
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Unknown status·FFirst Affiliated Hospital of Chengdu Medical College·Phase 1/2·NCT03013712·60 enrolled
2 more indications
Advanced1 trial
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT04121273·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAR-T cell immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- FFuda Cancer Hospital, Guangzhou